Glatiramer, CAS# 28704-27-0, and Glatiramer Acetate, CAS# 147245-92-9, are also known as Copaxone. In the spotlight recently, Copaxone’s patent is due to expire on May 24, 2014. The flurry of interest regarding Copaxone follows the devastating diagnosis of Multiple Sclerosis for beloved reality star Jack Osbourne. In mid June of 2012 reports surfaced about Jack’s new battle, which he was saddled with just three weeks after the birth of his daughter. Symptoms like a 60 percent sight loss in one eye and tingling in his extremities led this young man to seek medical attention. Typical symptoms of MS include inflammation in the brain and spinal cord, causing the loss of myelin or insulation around the nerves, as well as weakness, fatigue, vision loss, and numbness. The progression of MS is unknown and can vary with each patient, causing acute symptoms to be mild, moderate or severe. However, in the midst of the disturbing news there is hope. Glatiramer, or Copaxone, marketed by Teva, is a definite treatment option for Mr. Osbourne, according to reports at NBC.com. In addition to treatment with not only glatiramer acetate, patients like Jack have a variety of symptom easing medications, such as dexamethasone and prednisone for swelling and inflammation, and trazadone for depression and tremors.
Glatiramer Acetate is an immunomodulating drug, and is essentially an artificial protein that resembles a natural myelin protein. It is believed to be effectual by preventing the body’s immune system from attacking the myelin coating that protects nerve fibers in patients with MS. Given as an injection, subcutaneously once a day, glatiramer was formerly known as copolymer-1. Offered in a 20 milligram size, glatiramer may cause adverse effects such as diarrhea, headache, depression, nausea, vomiting, ear pain, joint pain and purple patches on the skin.
On June 14, 2012 Teva reported that goals from a late stage clinical trial recently were revealed, and pointed to a favorable outcome for patients taking Copaxone. Patients who took the newer version of glatiramer acetate were reported to be 34 percent less likely to have a symptom relapse. This study lasted a year, and compared patients who took a placebo, versus patients given glatiramer. With the patent for Copaxone set to expire in less then a year, this information is uplifting and reassuring to researchers, prescribers and patients. LGM Pharma is a provider of the API glatiramer acetate and glatiramer, and offers complete support to clients throughout the R&D process. As the Sole Distributor of Teva for their extensive API portfolio, for the US pharmacy compounding market, LGM Pharma looks forward to providing clients with TEVA products, as well as other quality API products.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.